The diabetes drugs market focuses on medications used to manage blood glucose levels in patients with type 1 and type 2 diabetes. This includes insulin therapies, oral hypoglycemics (such as metformin, sulfonylureas, SGLT-2 and DPP-4 inhibitors), and GLP-1 receptor agonists. With rising global diabetes prevalence, enhanced screening programs, and a growing emphasis on chronic disease management, demand for effective, safe, and affordable drug therapies continues to increase. Advances in drug formulations—like once-weekly injections and oral dosing options—along with improvements in patient access and adherence, are driving market growth worldwide.
According to Fortune Business Insights, the global diabetes drugs market was valued at USD 88.32 billion in 2024. The market is projected to grow from USD 101.48 billion in 2025 to USD 233.84 billion by 2032, exhibiting a CAGR of 12.7% during the forecast period. In 2024, North America dominated the diabetes drugs market with a market share of 49.95%.
Novo Nordisk, Eli Lilly, and Sanofi dominate, collectively controlling over half of the global market share.
In July 2024, Novo Nordisk received a Complete Response Letter (CRL) from the U.S. FDA regarding its Biologics License Application for once-weekly basal insulin icodec—a significant setback . While not an approval, it underscores the company’s effort to expand groundbreaking treatment options.